Abstract 1236: Biomarkers of response to abiraterone and the polo-like kinase 1 (PLK1) inhibitor onvansertib in metastatic castration resistant prostate cancer (mCRPC) patients
Authors: Maya Ridinger, Errin Samuelsz, Peter J. Croucher, Mark Erlander, Katherine Ruffner, David J. Einstein